Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal From Future Pak
Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal From Future Pak
No Shareholder Action Required at This Time
目前無需股東採取任何行動
WASHINGTON, May 7, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it has received a revised unsolicited proposal from Future Pak, LLC ("Future Pak") to acquire the Company. The revised proposal consists of a $7.25 to $7.75 per share in cash plus certain Contingent Value Rights ("CVRs"). The amended proposal follows Vanda's review and rejection of a prior unsolicited proposal from Future Pak to acquire the Company for $7.25-$7.75 per share.
華盛頓，2024年5月7日 /PRNewswire/ — 萬達製藥公司（“萬達” 或 “公司”）（納斯達克股票代碼：VNDA）今天證實，它已收到Future Pak, LLC（“Future Pak”）主動提出的收購該公司的修訂提案。修訂後的提案包括每股7.25至7.75美元的現金以及某些或有價值權利（“CVR”）。修訂後的提案是在Vanda審查並拒絕了Future Pak先前主動提出的以每股7.25美元至7.75美元收購公司的提議之後提出的。
Consistent with its fiduciary duties, and in consultation with its independent financial and legal advisors, Vanda's Board of Directors will carefully review and evaluate the revised unsolicited proposal to determine the course of action that it believes is in the best interests of Vanda and its shareholders.
根據其信託職責，經與其獨立財務和法律顧問協商，萬達董事會將仔細審查和評估經修訂的未經請求的提案，以確定其認爲符合萬達及其股東最大利益的行動方針。
Vanda does not intend to comment further on the revised, unsolicited proposal before the Board has completed its review.
在董事會完成審查之前，Vanda不打算對經修訂的未經請求的提案發表進一步評論。
There is no action for shareholders to take at this time.
股東目前沒有可採取任何行動。
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit and follow us on X @vandapharma.
關於萬達製藥公司
Vanda是一家全球領先的生物製藥公司，專注於創新療法的開發和商業化，以滿足未得到滿足的高度醫療需求並改善患者的生活。有關 Vanda Pharmicals Inc. 的更多信息，請訪問並在 X @vandapharma 上關注我們。
Vanda Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer Vanda Pharmaceuticals Inc.
202-734-3400
[email protected]
萬達公司聯繫人：
凱文·莫蘭
高級副總裁、首席財務官兼財務主管 Vanda Pharmicals Inc.
202-734-3400
[電子郵件保護]
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
[email protected]
吉姆·戈爾登/傑克·凱勒赫/丹·摩爾
收集的策略
[電子郵件保護]
SOURCE Vanda Pharmaceuticals Inc.
來源 Vanda 製藥公司
譯文內容由第三人軟體翻譯。